Results 211 to 220 of about 8,062,145 (231)

Human Induced Pluripotent Stem Cells in Rare Neurological Disorders: Opportunities and Challenges for Disease Modeling and Drug Discovery. [PDF]

Stem Cells Int
Harej Hrkać A, Rački V, Belančić A, Kriz J, Vitezić D, Mršić-Pelčić J, Acharya G, Varshney M, Pilipović K.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Antibody–Drug Conjugates: Smart Chemotherapy Delivery Across Tumor Histologies

Ca-A Cancer Journal for Clinicians, 2022
Shanu Modi, Javier Cortes, Jean-Charles Soria   +2 more
exaly  

Disentangling the Cost of Orphan Drugs Marketed in the United States

Healthcare, 2023
Enrique Seoane-Vazquez, Rosa Rodríguez-Monguió, Marc L Fleming   +2 more
exaly  

Epigenetics in Toxicology and Drug Development

Medical Epigenetics, 2021
exaly  

Europe Finally Agrees to Encourage Orphan-Drug Production

Lancet, The, 2000
Arthur Rogers
exaly  

Orphan Drug Development in Cardiovascular Medicine

Circulation: Cardiovascular Quality and Outcomes, 2020
Javed Butler, Muthiah Vaduganathan, Muhammad Shahzeb Khan   +2 more
exaly  

Flexibility in the FDA Approach to Orphan Drug Development

Nature Reviews Drug Discovery, 2017
Rachel E Sherman
exaly  

Clinical Pharmacology as a Cornerstone of Orphan Drug Development

Nature Reviews Drug Discovery, 2011
Edward Bashaw, Angela Y Men
exaly  

Worldwide Collaboration for Orphan Drug Designation

Nature Reviews Drug Discovery, 2016
Bruno Sepodes, Segundo Mariz, Kerstin Westermark   +2 more
exaly  

The Orphan Drug Pipeline in Europe

Nature Reviews Drug Discovery, 2016
Thomas Morel, Bruno Sepodes, David Cassiman   +2 more
exaly